Meera R. Hameed, MD
Pathologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
About Me
- Chief, Surgical Pathology Service
I am a pathologist with expertise in surgical pathology, molecular pathology, and clinical cytogenetics.
Read more
As a surgical pathologist, my particular expertise is bone and soft tissue (musculoskeletal) pathology. I work very closely with my clinical colleagues — including surgeons, radiologists, and medical oncologists. This collaboration has given me an in-depth understanding of clinical situations and has provided me the opportunity to participate as a team member with my clinical colleagues. I am an Invited Member of the International Skeletal Society — an organization of radiologists, pathologists, and surgeons who meet yearly to discuss rare and unusual presentations of the various bone and soft tissue neoplasms. I am also interested in teaching, and am a course co-director for orthopedic pathology at meetings of the U.S. and Canadian Academy of Pathology.
I am also a molecular pathologist with board certification in molecular genetic pathology, which allows me to keep abreast of latest developments in the fast-growing field of molecular oncology. As an invited member of the Molecular Oncology Committee of the College of American Pathologists, I serve as the committee member for the sarcoma sub-division and provide expertise on test development and appropriate molecular testing for sarcoma patients.
Clinical cytogenetics, in which I am also board certified, is a field where one studies chromosomal changes to interpret and provide pathological diagnostic correlations. My research involves exploring prognostic markers in bone and soft tissue neoplasms. For example, we have studied expression of markers with therapeutic significance, such as the EGFR family of tyrosine kinases in synovial sarcomas and osteosarcomas.
A pathologist is a doctor who uses a microscope to make a diagnosis from cell and tissue samples. They analyze the samples to learn the cause and effects of a health condition.
My Specialties
- Surgical Pathology
- Molecular Diagnostics
- Bone Cancer
- Soft Tissue Sarcoma
Education
- MD, Kilpaul Medical College Hospital (India)
Residencies
- Kilpauk Medical College Hospital
- Southern Railway Headquarters (India)
- Hahnemann University Hospital
Awards and Honors
- Castle Connolly: Top AAPI Doctor (2024)
- Castle Connolly: Exceptional Women in Medicine (2024)
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Exceptional Women in Medicine Award, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
Fellowships
- University of Connecticut Health Center
- Hahnemann University Hospital
- Memorial Sloan Kettering Cancer Center
Board Certifications
- Anatomic and Clinical Pathology
- Molecular Genetic Pathology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Request an Opinion
Contact and Location
Dr. Hameed sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
See all Molecular Diagnostics doctors
See all Surgical Pathology doctors
See all Pathology and Laboratory Medicine doctors
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Wang L, Zehir A, Sadowska J, Zhou N, Rosenblum M, Busam K, Agaram N, Travis W, Arcila M, Dogan S, Berger M, Cheng DT, Ladanyi M, Nafa K and Hameed M. Consistent copy number changes and recurrent PRKAR1A mutations distinguish melanotic schwannomas from melanomas: SNP array and next generation sequencing analysis. Genes Chromosomes Cancer. 2015; 54:463-471. PMC6446921.
Jour G, Wang L, Middha S, Zehir A, Chen W, Sadowska J, Healey J, Agaram NP, Choi L, Nafa K and Hameed M. The molecular landscape of extraskeletal osteosarcoma: a clinicopathological and molecular biomarker study. J. Pathol 2015; 2(1):9-20. PMC4858130.
Wang L, Zehir A, Nafa K, Zhou N, Berger MF, Casanova J, Sadowska J, Lu C, Allis DC, Gounder M, Chandhanayingyong C, Ladanyi M, Boland P and Hameed M. Genomic aberrations frequently alter chromatin regulatory genes in chordoma. Genes, Chromosomes, Cancer 2016 Jul 55(7):591-600. PMC5031498.
Hanna MG, Reuter VE, Ardon O, Kim D, Sirintrapun SJ, Schüffler PJ, Busam KJ, Sauter JL, Brogi E, Tan LK, Xu B, Bale T, Agaram NP, Tang LH, Ellenson LH, Philip J, Corsale L, Stamelos E, Friedlander MA, Ntiamoah P, Labasin M, England C, Klimstra DS, Hameed M. Validation of a digital pathology system including remote review during the COVID-19 pandemic. Mod Pathol. 2020 Jun 22:1-13Mod Pathol. 2020 Jun 22:1-13. PMID: 32572154
Patient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Meera R. Hameed discloses the following relationships and financial interests:
-
International Society of Bone and Soft Tissue Pathology
Fiduciary Role / Position
-
United States & Canadian Academy of Pathology, USCAP
Fiduciary Role / Position
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].